An investigation for investors in Novocure Ltd (NASDAQ:NVCR) shares over potential securities laws violations by Novocure Ltd was announced and NASDAQ:NVCR stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 01/05/2017 -- Novocure Ltd is under investigation over potential securities laws violations. The investigation was announced on behalf of investors in NASDAQ:NVCR shares in connection certain financial statements made by Novocure Ltd.
Investors who purchased shares of Novocure Ltd (NASDAQ:NVCR), have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call 858-779-1554.
The investigation by a law firm focuses on whether certain statements by Novocure Ltd regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On July 28, 2016, Novocure Ltd reported its second quarter 2016 financial result snad provided a company update. Among other things, Novocure Ltd reported that its new Optune prescriptions fell to 657 in the second quarter from 755 in the first quarter. Asaf Danziger, Chief Executive Officer of Novocure stated that "[w]hile barriers to full adoption remain, I am optimistic we will overcome the challenges inherent in bringing a completely new therapy into widespread clinical use."
On January 3, 2016, NASDAQ:NVCR shares closed at $7.85 per share.
Those who purchased shares of Novocure Ltd have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego